Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2341
- Registration Number
- NCT01507831
- Locations
- 🇺🇸
Investigational Site Number 840047, Houston, Texas, United States
🇺🇸Investigational Site Number 840076, Long Beach, California, United States
🇺🇸Investigational Site Number 840163, Santa Rosa, California, United States
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9
- Registration Number
- NCT01505062
- Locations
- 🇫🇷
Investigational Site Number 250001, Paris, France
🇺🇸Investigational Site Number 840001, Portland, Oregon, United States
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT01500720
- Locations
- 🇷🇴
Investigational Site Number 642001, Craiova, Romania
🇬🇷Investigational Site Number 300005, Athens, Greece
🇺🇸Investigational Site Number 840006, Lebanon, New Hampshire, United States
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: HOE901-U300 (new formulation of insulin glargine)
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 807
- Registration Number
- NCT01499082
- Locations
- 🇺🇸
Investigational Site Number 840036, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 840001, Dallas, Texas, United States
🇺🇸Investigational Site Number 840155, Baltimore, Maryland, United States
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: HOE901-U300 (new formulation of insulin glargine)
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 811
- Registration Number
- NCT01499095
- Locations
- 🇺🇸
Investigational Site Number 840074, Anaheim, California, United States
🇺🇸Investigational Site Number 840513, Pembroke Pines, Florida, United States
🇺🇸Investigational Site Number 840050, Idaho Falls, Idaho, United States
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01497964
- Locations
- 🇰🇷
Investigational Site Number 410001, Seoul, Korea, Republic of
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 81
- Registration Number
- NCT01496313
- Locations
- 🇨🇿
Investigational Site Number : 1903, Olomouc, Czechia
🇨🇿Investigational Site Number : 1901, Praha, Czechia
🇵🇱Investigational Site Number : 5704, Warsaw, Mazowieckie, Poland
Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine HOE901Drug: Insulin glargine - New formulation HOE901
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT01493115
- Locations
- 🇯🇵
Investigational Site Number 392001, Fukuoka-Shi, Japan
Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo (placebo for teriflunomide)
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT01487096
- Locations
- 🇨🇦
Canada, Toronto, Ontario, Canada
🇫🇷sanofi-aventis France, Lyon, France
Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: SAR407899A
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT01485900
- Locations
- 🇲🇩
Investigational Site Number 498002, Chisinau, Moldova, Republic of
🇷🇴Investigational Site Number 642001, Bucuresti, Romania